MPI/MRI bimodal imaging for non-invasive tracking of extracellular vesicles targeted to infarcted myocardium
MPI/MRI 双模成像,用于无创追踪梗塞心肌细胞外囊泡
基本信息
- 批准号:10366590
- 负责人:
- 金额:$ 48.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdvanced DevelopmentAnimal ModelAutologousBenchmarkingBiological AvailabilityCardiacCardiovascular DiseasesCause of DeathCellsComprehensionDetectionDevelopmentDilatation - actionElectroporationEngineeringEquipmentFutureGoalsHeartHeart InjuriesHistologicHomeHomingHot SpotImageImaging technologyImpairmentInjectableInjectionsInjuryInjury to KidneyInvestigationKnowledgeLabelMagnetic Resonance ImagingMagnetismMeasurementMeasuresMethodsMissionModelingMonitorMultimodal ImagingMusMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumNatureParticle SizePatientsPeptidesPerformancePhysiologic pulsePlayProceduresPropertyPublic HealthRegenerative MedicineRegenerative capacityReperfusion InjuryResearchResolutionRoleRouteSensitivity and SpecificitySignal TransductionSiteSourceSpatial DistributionSpecificitySpeedSurfaceTechnologyTherapeuticTherapeutic EffectTracerTranslationsTreatment outcomeTropismUnited StatesUnited States National Institutes of HealthValidationbasebioluminescence imagingclinical applicationclinical translationextracellular vesiclesfluorescence imagingheart functionimaging platformimprovedimproved functioningin vivoinduced pluripotent stem cellinjuredinnovationiron oxideiron oxide nanoparticlemyocardial infarct sizingnovelparacrineparticlepreclinical studyprototyperegenerative approachrepairedresearch clinical testingstem cell deliverystem cellssuccesssuperparamagnetismtherapy outcometreatment strategyuptakevesicular release
项目摘要
Project summary
Stem cells derived extracellular vesicles (EV) hold great promise for repairing myocardial infarctions (MI), and
there is an urgent need to develop effective EV-based therapies, preferably delivered by systemic administration.
In this context, a robust EV-tracking technology is invaluable to provide the new capability to elucidate the injury
tropism of EVs derived from different cell sources and to guide and further optimize EV-based therapies. The
goal of this Catalyze proposal is to establish a bimodal imaging platform technology for tracking EV delivery to
the injured heart using magnetic resonance imaging (MRI) and magnetic particle imaging (MPI). In our
preliminary studies, we developed a novel labeling strategy for preparing highly purified, magnetically labeled
EVs, dubbed magneto-EVs. Thanks to the magnetic labeling by superparamagnetic iron oxide (SPIO)
nanoparticles, one can use combined MRI and MPI to detect systemically injected EVs in vivo with high sensitivity
and specificity in a high spatial resolution manner. In this Catalyze proposal, we will further optimize and
rigorously validate the MPI/MRI technologies for tracking magneto-EVs beyond the initial prototype
demonstration. In particular, we will 1) optimize magnetic labeling and MPI/MRI acquisition for accurately
detecting magneto-EVs and 2) validate the ability of MPI/MRI to track therapeutic EVs in a mouse MI model.
This line of investigation is significant because it will fill the critical gap in knowledge as to how to track and
improve EV for myocardial repair applications, and this new MPI/MRI has the capability, if optimized, to meet the
unmet need, that is an effective means to investigate the injury-tropism of SC-EVs and thereby promote the
development of more effective, EV-based regenerative medicine for myocardial repair. Furthermore, MRI has
immediate translatability and will facilitate the clinical application of EV therapies in the future, whereas MPI also
has translation potential. The proposed research is innovative because the proposed study will use a novel
labeling strategy, which allows preparing highly purified magneto-EVs efficiently, and an MPI/MRI multimodal
detection approach, which enables quantitative tracking of magneto-EVs in vivo in a high spatial resolution
manner.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guanshu Liu其他文献
Guanshu Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guanshu Liu', 18)}}的其他基金
MPI/MRI bimodal imaging for non-invasive tracking of extracellular vesicles targeted to infarcted myocardium
MPI/MRI 双模成像,用于无创追踪梗塞心肌细胞外囊泡
- 批准号:
10557225 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别:
CEST MRI assessment of tumor vascular permeability using non-labeled dextrans
使用非标记葡聚糖评估肿瘤血管通透性的 CEST MRI
- 批准号:
9297917 - 财政年份:2017
- 资助金额:
$ 48.71万 - 项目类别:
Noninvasive prediction of tumor response to gemcitabine using MRI
使用 MRI 无创预测肿瘤对吉西他滨的反应
- 批准号:
9328948 - 财政年份:2017
- 资助金额:
$ 48.71万 - 项目类别:
Optimization of CEST MRI for detection of bacteria
用于细菌检测的 CEST MRI 优化
- 批准号:
9303352 - 财政年份:2016
- 资助金额:
$ 48.71万 - 项目类别:
Monitoring Prodrug Delivery in Suicide Gene Therapy Using CEST MRI
使用 CEST MRI 监测自杀基因治疗中的前药递送
- 批准号:
8510646 - 财政年份:2012
- 资助金额:
$ 48.71万 - 项目类别:
Monitoring Prodrug Delivery in Suicide Gene Therapy Using CEST MRI
使用 CEST MRI 监测自杀基因治疗中的前药递送
- 批准号:
8356569 - 财政年份:2012
- 资助金额:
$ 48.71万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 48.71万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 48.71万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 48.71万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 48.71万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 48.71万 - 项目类别: